These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37541133)

  • 1. Plasma neurofilament light-chain and phosphorylated tau as biomarkers of disease severity in Huntington's disease: Korean cohort data.
    Hwang YS; Oh E; Kim M; Lee CY; Kim HS; Chung SJ; Sung YH; Yoon WT; Cho JH; Lee JH; Kim HJ; Chang HJ; Jeon B; Woo KA; Ko SB; Kwon KY; Moon J; Shin C; Kim YE; Lee JY
    J Neurol Sci; 2023 Sep; 452():120744. PubMed ID: 37541133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tau or neurofilament light-Which is the more suitable biomarker for Huntington's disease?
    Niemelä V; Landtblom AM; Blennow K; Sundblom J
    PLoS One; 2017; 12(2):e0172762. PubMed ID: 28241046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations between prognostic index scores and plasma neurofilament light in Huntington's disease.
    Parkin GM; Corey-Bloom J; Long JD; Snell C; Smith H; Thomas EA
    Parkinsonism Relat Disord; 2022 Apr; 97():25-28. PubMed ID: 35276585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Blood Glial Fibrillary Acidic Protein as a Potential Marker in Huntington's Disease.
    You H; Wu T; Du G; Huang Y; Zeng Y; Lin L; Chen D; Wu C; Li X; Burgunder JM; Pei Z
    Front Neurol; 2021; 12():779890. PubMed ID: 34867769
    [No Abstract]   [Full Text] [Related]  

  • 5. Plasma neurofilament light in Huntington's disease: A marker for disease onset, but not symptom progression.
    Parkin GM; Corey-Bloom J; Snell C; Castleton J; Thomas EA
    Parkinsonism Relat Disord; 2021 Jun; 87():32-38. PubMed ID: 33940564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 14-year longitudinal study of neurofilament light chain dynamics in premanifest and transitional Huntington's disease.
    Voysey ZJ; Owen NE; Holbrook JA; Malpetti M; Le Draoulec C; Spindler LRB; Goodman AOG; Lazar AS; Barker RA
    J Neurol; 2024 Dec; 271(12):7572-7582. PubMed ID: 39361164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma NfL as a prognostic biomarker for enriching HD-ISS stage 1 categorisation: a cross-sectional study.
    Parkin GM; Thomas EA; Corey-Bloom J
    EBioMedicine; 2023 Jul; 93():104646. PubMed ID: 37315450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis.
    Byrne LM; Rodrigues FB; Blennow K; Durr A; Leavitt BR; Roos RAC; Scahill RI; Tabrizi SJ; Zetterberg H; Langbehn D; Wild EJ
    Lancet Neurol; 2017 Aug; 16(8):601-609. PubMed ID: 28601473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease.
    Rodrigues FB; Byrne L; McColgan P; Robertson N; Tabrizi SJ; Leavitt BR; Zetterberg H; Wild EJ
    J Neurochem; 2016 Oct; 139(1):22-5. PubMed ID: 27344050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping neurodegeneration across the Huntington's disease spectrum: a five-year longitudinal analysis of plasma neurofilament light.
    Parkin GM; Thomas EA; Corey-Bloom J
    EBioMedicine; 2024 Jun; 104():105173. PubMed ID: 38815362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurofilament Light Protein as a Potential Blood Biomarker for Huntington's Disease in Children.
    Byrne LM; Schultz JL; Rodrigues FB; van der Plas E; Langbehn D; Nopoulos PC; Wild EJ
    Mov Disord; 2022 Jul; 37(7):1526-1531. PubMed ID: 35437792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application Value of Serum Neurofilament Light Protein for Disease Staging in Huntington's Disease.
    Li XY; Bao YF; Xie JJ; Gao B; Qian SX; Dong Y; Wu ZY
    Mov Disord; 2023 Jul; 38(7):1307-1315. PubMed ID: 37148558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma neurofilament light as a promising biomarker in neuronal intranuclear inclusion disease.
    Liu M; Zhu Y; Yuan Y; Wang Y; Liu X; Li L; Gao Y; Yan H; Liu R; Cheng L; Yuan J; Wang Q; Li S; Liu Y; Wang Y; Shi C; Xu Y; Yang J
    J Neurol; 2024 Apr; 271(4):2042-2052. PubMed ID: 38189920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington's disease.
    Byrne LM; Rodrigues FB; Johnson EB; Wijeratne PA; De Vita E; Alexander DC; Palermo G; Czech C; Schobel S; Scahill RI; Heslegrave A; Zetterberg H; Wild EJ
    Sci Transl Med; 2018 Sep; 10(458):. PubMed ID: 30209243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tongue force analysis assesses motor phenotype in premanifest and symptomatic Huntington's disease.
    Reilmann R; Bohlen S; Klopstock T; Bender A; Weindl A; Saemann P; Auer DP; Ringelstein EB; Lange HW
    Mov Disord; 2010 Oct; 25(13):2195-202. PubMed ID: 20645403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid sCD27 levels indicate active T cell-mediated inflammation in premanifest Huntington's disease.
    Niemelä V; Burman J; Blennow K; Zetterberg H; Larsson A; Sundblom J
    PLoS One; 2018; 13(2):e0193492. PubMed ID: 29474427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early grey matter changes in structural covariance networks in Huntington's disease.
    Coppen EM; van der Grond J; Hafkemeijer A; Rombouts SA; Roos RA
    Neuroimage Clin; 2016; 12():806-814. PubMed ID: 27830113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurofilament light protein in CSF and blood is associated with neurodegeneration and disease severity in Huntington's disease R6/2 mice.
    Soylu-Kucharz R; Sandelius Å; Sjögren M; Blennow K; Wild EJ; Zetterberg H; Björkqvist M
    Sci Rep; 2017 Oct; 7(1):14114. PubMed ID: 29074982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Translatable plasma and CSF biomarkers for use in mouse models of Huntington's disease.
    Bondulich MK; Phillips J; Cañibano-Pico M; Nita IM; Byrne LM; Wild EJ; Bates GP
    Brain Commun; 2024; 6(1):fcae030. PubMed ID: 38370446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cortical microstructural correlates of plasma neurofilament light chain in Huntington's disease.
    Sampedro F; Pérez-Pérez J; Martínez-Horta S; Pérez-González R; Horta-Barba A; Campolongo A; Izquierdo C; Pagonabarraga J; Gómez-Ansón B; Kulisevsky J
    Parkinsonism Relat Disord; 2021 Apr; 85():91-94. PubMed ID: 33770670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.